Posts Tagged ‘OPXA’

OPXA pops, CSCO does business, MTG slumps

Wednesday, January 19th, 2011

Opexa Therapeutics Inc. (Nasdaq: OPXA) saw its price pop 18.1 percent to $2.48 Wednesday afternoon. Volume of 1,738,310 shares overwhelmed a full-day volume average of 269,989. OPXA is preparing to start a Phase 3 clinical study of its Tovaxin drug candidate for multiple sclerosis

Cisco Systems Inc. (Nasdaq: CSCO) traded Wednesday in 33,840,714 shares, only about half its full-day average. Prices for CSCO fell 1.9 percent to $20.82. CSCO announced Wednesday it will bring its fancy videoconference systems for teaching to several universities in Colorado, giving students at some remote, rural schools access to more classes.

MGIC Investment Corporation (NYSE: MTG) listed lower by 18.8 percent Wednesday to $9.46. Volume was 16,430,897 shares, four times its normal daily volume, on word that higher claims paid out last year hurt the company’s bottom line.

OPXA soars, C deals, TSTY turns south

Wednesday, January 5th, 2011

Opexa Therapeutics Inc. (Nasdaq: OPXA) shares leaped 80.8 percent to $2.82. Volume of 3.2 million shares, triumphed over usual volume of 70,317. The Woodlands, Texas-based cell therapy company said that after meeting twice with the U.S. Food and Drug Administration, it is preparing a Phase III clinical study of Tovaxin, a drug intended to treat multiple sclerosis.

Citigroup (NYSE:C) was a volume leader Wednesday, trading in 122,929,357, gaining on a full-day average of 538,020,000. Shares gained 0.7 percent to $4.94.

Tasty Baking Company (Nasdaq: TSTY) shed 33 percent to $4.31, on 159,504, compared to usual volume of below 10,000. TSTY announced today that preliminary financial data indicate the Company did not achieve the expected operational cash savings from this bakery during the fourth quarter.

Opexa Therapeutics Inc (Nasdaq: OPXA) Buzz Stock of the Day

Tuesday, September 14th, 2010

Opexa TherapeuticsWe originally covered Opexa Therapeutics in September of 09, today Opexa (Nasdaq: OPXA) shares surged as much as 23.4%  to a high of $1.95 ahead of the stem cell research firm’s presentation this afternoon at the Rodman & Renshaw healthcare conference. Neil K. Warma, Opexa’s President and Chief Executive Officer will deliver a corporate presentation that will include an overview of the Company’s ongoing clinical development program for Tovaxin, the Company’s lead therapy for Multiple Sclerosis (MS).

In addition to Opexa’s corporate presentation, other contributing factors are at play in the Company’s surging share prices. Vista Partners, a research and consulting firm, announced Monday that it has initiated coverage on Opexa Therapeutics with a twelve month target price of $4.40, representing a 300% premium to Friday’s closing value.
Ross Silver, Principal Analyst at Vista Partners stated, “Opexa’s lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, has shown promising clinical data to date.” Silver went on to address Opexa’s stem cell therapy partnership with Novartis (NYSE: NVS) stating that approval of other autologous cellular immunotherapy treatments, most notably Dendreon’s Provenge, has increased knowledge and acceptance of stem cell therapies and would “likely increase Opexa’s value amongst potential partners.”

Lastly, ongoing court battles over federally funded stem cell research have been affecting the Stem Cell Stocks Index, which is trading down -2.5% for the past 30 days. At the end of last month, all 11 of the Stem Cell Stocks Index components are -30% from their 52-week high with Opexa Therapeutics more than -60% from its peak.

Opexa Therapeutics Inc (OPXA) Buzz Stock of the Day

Tuesday, September 8th, 2009

Shares of Opexa Therapeutics, Inc.(NASDAQ: OPXA) were up more than 150 percent from Friday’s close in morning trading on Tuesday, after the company announced that more than 83 percent of patients taking its experimental multiple sclerosis drug, Tovaxin, remained relapse-free after one-year.

In addition, the annualized relapse rate among patients who took Tovaxin fell to 20 percent, a 42 percent reduction compared with the placebo. Tovaxin also showed stabilization and improvement of MS-related disabilities in 73 percent of patients, 16.5 percent of which showed sustained improvement of a least one full point on a standard disability scale.

The data was based on a 52-week Phase IIb clinical study that targeted 150 patients with relapsing, remitting multiple sclerosis, typically the initial stage of the disease. Patients in this stage of multiple sclerosis often experience unpredictable relapses, often followed by months or years of dormancy.

“Clinical benefits include not only reduction in relapses, but a surprising reversal of disability in over 16 percent of Tovaxin-treated patients,” said Dawn McGuire, MD, a board certified neurologist and a member of Opexa’s Clinical Advisory Board.

Opexa said it plans to recruit similar patients for another Phase IIb study of Tovaxin, which is a vaccine tailored to individual patients. The drug helps limit attacks by immune system cells called T-cells on myelin, the protein sheath that protects nerves.

Opexa’s news today carried the Stem Cell Stock Index 9.3 percent higher today. The Index, which is compilation of companies using stem cells to develop treatments, is currently ahead of the S&P 500 by 2.7% over the last month.